5 Biotech Stocks to Buy According to Matthew Strobeck’s Birchview Capital

Page 5 of 5

1. Accelerate Diagnostics, Inc. (NASDAQ:AXDX)

Birchview Capital Stake Value: $13,096,000
Percentage of Birchview Capital’s 13F Portfolio: 8.91%
Number of Hedge Fund Holders: 8

Accelerate Diagnostics, Inc. (NASDAQ:AXDX) is an in vitro diagnosis firm specializing in infectious pathogen fast diagnostics. According to the 13F filings for the third quarter of 2021, Birchview Capital holds over 2.25 million shares of Accelerate Diagnostics, Inc. (NASDAQ:AXDX), amounting to more than $13.10 million, representing 8.91% of the fund’s portfolio value.

Craig-Hallum analyst Alex Novak cut his price objective for Accelerate Diagnostics, Inc. (NASDAQ:AXDX) from $12 to $9 on January 14, and maintained a Buy recommendation on the stock. The company’s preannounced results, the analyst wrote in a research note, were a continuation of prior quarters as the firm struggled amid COVID-19 breakouts.

Overall, 8 hedge funds monitored by Insider Monkey were bullish on Accelerate Diagnostics, Inc. (NASDAQ:AXDX) in the third quarter. The stakes held by these funds are valued at $18.04 million.

You can also take a peek at 10 Best Biotech Stocks to Buy According to Joseph Edelman’s Perceptive Advisors and 9 Latest Stock Picks of Chinese Billionaire Chen Tianqiao’s Shanda Asset Management.

Page 5 of 5